Table 2 Post-treatment Change in Primary Outcomes

NESB MidEast

12.88 [10.96, 14.81]

6.33 [4.47, 8.19]

51% [36, 65%]

.46

.68

20% (β = − 0.84)

1.13 [0.95, 1.32]

0.16 [0.04, 0.28]

11% [−20, 35%]

NESB Europe

13.05 [12.01, 14.1]

7.3 [6.28, 8.31]

44% [36, 52%]

.29

.38

20% (β = − 0.84)

1.08 [0.97, 1.2]

−0.03 [− 0.1, 0.05]

−2% [−19, 12%]

NESB Asia

12.79 [11.92, 13.67]

5.78 [4.72, 6.85]

55% [46, 63%]

.069

.12

40% (β = − 0.25)

1.35 [1.26, 1.45]

0.26 [0.2, 0.32]

19% [2, 33%]

NESB English

13.69 [13.06, 14.32]

6.87 [6.23, 7.51]

50% [45, 54%]

.88

.46

30% (β = −0.52)

1.28 [1.21, 1.35]

0.05 [0.01, 0.1]

4% [−8, 14%]

ESB English

13.48 [13.14, 13.83]

6.32 [6.0, 6.63]

53% [51, 56%]

.41

.001

90% (β = 1.28)

1.43 [1.39, 1.47]

0.15 [0.12, 0.18]

11% [6, 17%]

AusBorn

13.64 [13.49, 13.8]

7.13 [6.82, 7.43]

48% [46, 50%]

–

–

–

1.2 [1.18, 1.22]

–

–

GAD7

Pre EMM (95%CI)

Post EMM (95%CI)

∆%@ Pre-Post [95%CI]

Test of baseline scores differences (p-value)

Test of rate of change (p-value)

Achieved statistical power

Within group ES -Hedge’s g pre-post [95%CI]

Between group ES - Hedge’s g @post [95%CI]

Between group ∆% @ Pre-Post^a

[95%CI]

NESB MidEast

11.44 [9.8, 13.09]

5.58 [3.16, 8]

51% [30, 72%]

.53

.071

20% (β = −0.84)

1.09 [0.91, 1.28]

0.16 [0.04, 0.28]

12% [−35, 42%]

NESB Europe

11.91 [10.95, 12.87]

6.75 [5.31, 8.19]

43% [31, 55%]

.88

.45

20% (β = −0.84)

1.07 [0.95, 1.18]

−0.11 [− 0.19, − 0.04]

−8% [−34, 14%]

NESB Asia

11.43 [10.68, 12.18]

5.18 [4.49, 5.87]

55% [49, 61%]

.16

.057

25% (β = − 0.68)

1.39 [1.3, 1.49]

0.25 [0.19, 0.31]

17% [4, 29%]

NESB English

11.55 [10.99, 12.11]

6.19 [5.56, 6.81]

46% [41, 52%]

.14

.59

30% (β = −0.52)

1.12 [1.06, 1.19]

0.02 [−0.03, 0.06]

1% [−8, 10%]

ESB English

11.83 [11.53, 12.13]

5.72 [5.45, 5.99]

52% [49, 54%]

.35

.006

90% (β = 1.28)

1.37 [1.33, 1.41]

0.12 [0.09, 0.15]

9% [4, 13%]

AusBorn

11.99 [11.86, 12.12]

6.26 [6.02, 6.5]

48% [46, 50%]

–

–

–

1.25 [1.23, 1.27]

–

–